All 9 /Events 0 /In The News 7 /Press Releases 2

NRG Therapeutics expands team with CDO appointment

thepharmaletter

Read  more
2 December 2025/by Webadm

NRG Therapeutics Announces Further Expansion with the Appointment of Paul Thompson as Chief Development Officer

Stevenage, UK, 1 December 2025 - NRG Therapeutics Ltd. (“NRG”),…
1 December 2025/by Webadm

NRG Therapeutics appoints Paul Thompson as CDO

Drug Discovery World

Read more
1 December 2025/by Webadm

UK Life Sciences Future50 – Momentum in an evolving landscape

pwc

Read more
(pdf)
30 November 2025/by Webadm

11 neuroscience biotech companies you should know about

Labiotech

Read more
25 November 2025/by Webadm

NRG Therapeutics Announces Senior Appointments as it Advances NRG5051 Towards First-in-Human Clinical Studies

Stevenage, UK, 23 October 2025 - NRG Therapeutics Ltd. (“NRG”),…
23 October 2025/by Webadm

Is this mitochondria’s big moment?

Longevity Technology

Read more
9 October 2025/by Webadm

Biotechs, BIA, patient charities and investors: the power of relationships

BIA, UK BioIndustry Association

Read more
8 October 2025/by Webadm

NRG Therapeutics: Restoring motor neuron function via mitochondria

BioCentury

Read more
(behind a paywall)
1 October 2025/by Webadm

TRICALS Masterclass 2026

TRICALS Masterclass 2026 11-13 Febuary 2026 Amsterdam, Netherlands View…

Scrip Asks… What Does 2026 Hold For Biopharma? Part 4: R&D Innovation

SCRIP Read more

Founder-CEO Interview Series

Sejelas Read more

Disease-modifying treatment for ALS enters Phase I

Drug Discovery World Read more

Target ALS Grantee NRG Therapeutics Advances NRG5051 into Phase I Clinical Trial

Target ALS Read more

44th Annual J.P. Morgan Healthcare Conference

44th Annual J.P. Morgan Healthcare Conference 12-15 January…

NRG doses first volunteers in mitochondrial ALS trial

Longevity Technology Read more

NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’s

Stevenage, UK, 8 January 2026 - NRG Therapeutics Ltd. (“NRG”),…